Characteristics and clinical trial results of agonistic anti‑CD40 antibodies in the treatment of malignancies (Review)
- Authors:
- Da-Ke Li
- Wen Wang
-
Affiliations: Department of Clinical Science, Shanghai R&D Center, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co. Ltd., Shanghai 201318, P.R. China - Published online on: August 31, 2020 https://doi.org/10.3892/ol.2020.12037
- Article Number: 176
-
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Clark EA and Ledbetter JA: Amplification of the immune response by agonistic antibodies. Immunol Today. 7:267–270. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Smith CA, Farrah T and Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell. 76:959–962. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Gauchat JF, Aubry JP, Mazzei G, Life P, Jomotte T, Elson G and Bonnefoy JY: Human CD40-ligand: Molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett. 315:259–266. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Galy A and Spits H: CD40 is functionally expressed on human thymic epithelial cells. J Immunol. 149:775–782. 1992.PubMed/NCBI | |
|
Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D and Chess L: Functional interactions of T cells with endothelial cells: The role of CD40L-CD40-mediated signals. J Exp Med. 182:1857–1864. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Costello RT, Gastaut JA and Olive D: What is the real role of CD40 in cancer immunotherapy? Immunol Today. 20:488–493. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ziebold JL, Hixon J, Boyd A and Murphy WJ: Differential effects of CD40 stimulation on normal and neoplastic cell growth. Arch Immunol Ther Exp (Warsz). 48:225–233. 2000.PubMed/NCBI | |
|
Graf D, Müller S, Korthäuer U, van Kooten C, Weise C and Kroczek RA: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 25:1749–1754. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
André P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR and Wagner DD: CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 8:247–252. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Eliopoulos AG and Young LS: The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 4:360–367. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hafeez U, Gan HK and Scott AM: Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr Opin Pharmacol. 41:114–121. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK and Murphy WJ: Inhibition of human B-Cell lymphoma growth by CD40 stimulation. Blood. 83:2787–2794. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR and Glennie MJ: T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol. 168:2720–2728. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hellstrom I and Hellstrom KE: Monoclonal antibodies for cancer therapy. Schwab M: Encyclopedia of Cancer. Springer; Berlin, Heidelberg, Germany: 2014, View Article : Google Scholar : PubMed/NCBI | |
|
Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J and Bataille R: CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res. 56:1909–1916. 1996.PubMed/NCBI | |
|
Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH and Young LS: CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol. 20:5503–5515. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Park CI, Hirono I, Hwang JY and Aoki T: Characterization and expression of a CD40 homolog gene in Japanese flounder Paralichthys olivaceus. Immunogenetics. 57:682–689. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR and Alber T: Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA. 96:8408–8413. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Berberich I, Shu GL and Clark EA: Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol. 153:4357–4366. 1994.PubMed/NCBI | |
|
Berberich I, Shu G, Siebelt F, Woodgett JR, Kyriakis JM and Clark EA: Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. EMBO J. 15:92–101. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Ren CL, Morio T, Fu SM and Geha RS: Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med. 179:673–680. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Li YY, Baccam M, Waters SB, Pessin JE, Bishop GA and Koretzky GA: CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. J Immunol. 157:1440–1447. 1996.PubMed/NCBI | |
|
Notarangelo LD, Peitsch MC, Abrahamsen TG, Bachelot C, Bordigoni P, Cant AJ, Chapel H, Clementi M, Deacock S, de Saint Basile G, et al: CD40lbase: A database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today. 17:511–516. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Villa A, Notarangelo LD, Di Santo JP, Macchi PP, Strina D, Frattini A, Lucchini F, Patrosso CM, Giliani S, Mantuano E, et al: Organization of the human CD40L gene: Implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. Proc Natl Acad Sci USA. 91:2110–2114. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Schönbeck U and Libby P: The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 58:4–43. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Grewal IS and Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 16:111–135. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Tong AW and Stone MJ: Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10:1–13. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A and Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 184:747–752. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM and Rakhmilevich AL: In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 79:1181–1192. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Arango Duque G and Descoteaux A: Macrophage cytokines: Involvement in immunity and infectious diseases. Front Immunol. 5:4912014. View Article : Google Scholar : PubMed/NCBI | |
|
Stow JL, Low PC, Offenhäuser C and Sangermani D: Cytokine secretion in macrophages and other cells: Pathways and mediators. Immunobiology. 214:601–612. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
van Kooten C and Banchereau J: Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 9:330–337. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Arpin C, Déchanet J, Van Kooten C, Merville P, Grouard G, Brière F, Banchereau J and Liu YJ: Generation of memory B cells and plasma cells in vitro. Science. 268:720–722. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH and Irish JM: Human germinal center B cells differ from naive and memory B cells in CD40 expression and CD40L-induced signaling response. Cytometry A. 95:442–449. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hill A and Chapel H: X-linked immunodeficiency. The fruits of cooperation. Nature. 361:4941993. View Article : Google Scholar : PubMed/NCBI | |
|
Vonderheide RH: Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 13:1083–1088. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Planken EV, Dijkstra NH, Bakkus M, Willemze R and Kluin-Nelemans JC: Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen. Br J Haematol. 95:319–326. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Murphy WJ, Funakoshi S, Fanslow WC, Rager HC, Taub DD and Longo DL: CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras. Clin Immunol. 90:22–27. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Voorzanger-Rousselot N, Favrot M and Blay JY: Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood. 92:3381–3387. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Castillo R, Mascarenhas J, Telford W, Chadburn A, Friedman SM and Schattner EJ: Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia. 14:292–298. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kusam S, Munugalavadla V, Sawant D and Dent A: BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells. Int J Cancer. 125:977–981. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C and Banchereau J: Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 182:1265–1273. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Schattner EJ, Mascarenhas J, Bishop J, Yoo DH and Friedman SM: CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood. 88:1375–1382. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G: NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA. 96:9136–9141. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC and Kipps TJ: Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:3854–3859. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y and Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 229:152–172. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Piechutta M and Berghoff AS: New emerging targets in cancer immunotherapy: The role of Cluster of Differentiation 40 (CD40/TNFR5). ESMO Open. 4:e0005102019. View Article : Google Scholar : PubMed/NCBI | |
|
French RR, Chan HC, Tutt AL and Glennie MJ: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nature medicine. 5:548–553. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG and Glennie MJ: CD40 ligation for immunotherapy of solid tumours. J Immunol Methods. 248:139–147. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Remer M, White A, Glennie M, Al-Shamkhani A and Johnson P: The use of anti-CD40 mAb in cancer. Curr Top Microbiol Immunol. 405:165–207. 2017.PubMed/NCBI | |
|
Vonderheide RH: CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 71:47–58. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, et al: Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 187:1754–1763. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson M, Fakih M, Bendell J, Bajor D, Cristea M, Tremblay T, Trifan O and Vonderheide R: First in human study with the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors. J Immuno Ther Cancer. 5:892017. | |
|
Richman LP and Vonderheide RH: Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res. 2:19–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
White AL, Chan HC, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al: Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell. 27:138–148. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, Zhang H, He Y, Lu B, Jin T and Li F: Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nat Commun. 10:42062019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Chan HC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, et al: Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell. 33:664–675. e664. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Tu GH, Wei J, Santiago P, Larrabee LR, Liao-Chan S, Mistry T, Chu ML, Sai T, Lindquist K, et al: Ligand-blocking and membrane-proximal domain targeting anti-OX40 antibodies mediate potent T cell-stimulatory and anti-tumor activity. Cell Rep. 27:3117–3123. e3115. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH and O'Dwyer PJ: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 19:6286–6295. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW and Hamid O: Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2:e230332013. View Article : Google Scholar : PubMed/NCBI | |
|
Nowak A, Cook A, McDonnell A, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, et al: A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 26:2483–2490. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Furman RR, Forero-Torres A, Shustov A and Drachman JG: A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 51:228–235. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E and Drachman JG: Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: A randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 56:2569–2578. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, et al: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol. 7:442014. View Article : Google Scholar : PubMed/NCBI | |
|
Irenaeus SMM, Nielsen D, Ellmark P, Yachnin J, Deronic A, Nilsson A, Norlén P, Veitonmäki N, Wennersten CS and Ullenhag GJ: First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J Cancer. 145:1189–1199. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 25:876–883. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gladue RP, Paradis T, Cole SH, Donovan C, Nelson R, Alpert R, Gardner J, Natoli E, Elliott E, Shepard R and Bedian V: The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 60:1009–1017. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, et al: CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother. 33:810–816. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rüter J, Antonia SJ, Burris HA, Huhn RD and Vonderheide RH: Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 10:983–993. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W and Repasky EA: Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 61:7556–7562. 2001.PubMed/NCBI | |
|
Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ and Kedl RM: Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 199:775–784. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H and Smyth MJ: Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 12:6932006. View Article : Google Scholar : PubMed/NCBI | |
|
Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr and Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 94:8789–8794. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M and Wilkinson RW: Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. 7:185082016. View Article : Google Scholar : PubMed/NCBI | |
|
Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, et al: Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 7:e14689562018. View Article : Google Scholar : PubMed/NCBI | |
|
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 31:616–622. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Khubchandani S, Czuczman MS and Hernandez-Ilizaliturri FJ: Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs. 10:579–587. 2009.PubMed/NCBI | |
|
Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, et al: Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65:8331–8338. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS and Gerber HP: Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer. 100:113–117. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N and Drachman JG: Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 27:4371–4377. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF and Moskowitz CH: Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 54:277–283. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Geldart TR, Harvey M, Carr N, Glennie M and Johnson P: Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: Evidence of preclinical efficacy. J Clin Oncol. 22:2577. 2004. View Article : Google Scholar | |
|
Johnson PW, Challis R, Chowdhury F, Chan C, Smith A, Steven N, Edwards C, Ashton-Key M, Hodges E, Tutt A, et al: Abstract LB-142: A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study. Cancer Res. 73:2013. | |
|
Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH and Ellmark P: The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res. 21:1115–1126. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, et al: Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 68:233–245. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Santuray RT, Johnson DE and Grandis JR: New therapies in head and neck cancer. Trends Cancer. 4:385–396. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bjorck P, Filbert E, Zhang Y, Yang X and Trifan O: The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities. J Immunother Cancer. 3:P1982015. View Article : Google Scholar |
